AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34746424 — intervention group
Group type: COMPARATOR
Intervention: Standardized blood pressure management (systolic blood pressure target range 140-180 mmHg)
Number of subjects: 0
Study 34746674 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar Locking Plate
Number of subjects: 156
Study 34746674 — intervention group
Group type: EXPERIMENTAL
Intervention: External Fixator
Number of subjects: 156
Study 34746723 — intervention group
Group type: EXPERIMENTAL
Intervention: ORBCEL-C (100, 200, or 400 × 10^6 cells)
Number of subjects: 9
Study 34746886 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus Pembrolizumab (Cohort A)
Number of subjects: 50
Study 34746886 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus Pembrolizumab (Cohort B)
Number of subjects: 50
Study 34746903 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg plus ezetimibe 10 mg fixed-dose combination (BA + EZE FDC)
Number of subjects: 179
Study 34746903 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg
Number of subjects: 179
Study 34746903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 34746970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric age-specific PET template (PAPT)
Number of subjects: 130
Study 34747267 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Oxygen Therapy (Natrox)
Number of subjects: 0
Study 34747267 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34747649 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34747691 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended sleep study with an auto-adjusting mandibular positioner
Number of subjects: 58
Study 34747691 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence method
Number of subjects: 58
Study 34747699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrepid TMVR system
Number of subjects: 15
Study 34747701 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-Controlled Digital Game (SCDG) intervention
Number of subjects: 38
Study 34747701 — intervention group
Group type: COMPARATOR
Intervention: Sensors-only intervention
Number of subjects: 38
Study 34747704 — intervention group
Group type: EXPERIMENTAL
Intervention: NettOpp mobile app intervention
Number of subjects: 0
Study 34747704 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study 34748144 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 players
Number of subjects: 42
Study 34748144 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID-19 players
Number of subjects: 42
Study 34748385 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine, dosage and duration not specified
Number of subjects: 0
Study 34748385 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34748572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox-eflornithine combination therapy (NECT)
Number of subjects: 629
Study 34748634 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe insulin-resistant diabetes (SIRD)
Number of subjects: 746
Study 34748634 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe autoimmune diabetes (SAID)
Number of subjects: 746
Study 34748634 — intervention group
Group type: COMPARATOR
Intervention: Glucose-tolerant control (CON)
Number of subjects: 746
Study 34748672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 600 mg intravenous every 24 weeks for 96 weeks
Number of subjects: 680
Study 34748951 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ml Extra Virgin Olive Oil (EVOO) daily for one year
Number of subjects: 0
Study 34748951 — intervention group
Group type: COMPARATOR
Intervention: Not administered EVOO (Control group)
Number of subjects: 0
Study 34749516 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Diameter Advanta V12 covered stent
Number of subjects: 70
Study 34749638 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache free participants
Number of subjects: 99
Study 34749638 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 99
Study 34749654 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturday shift visits
Number of subjects: 16651
Study 34749654 — intervention group
Group type: COMPARATOR
Intervention: Regular weekday shifts
Number of subjects: 16651
Study 34749654 — intervention group
Group type: COMPARATOR
Intervention: Late weekday shifts
Number of subjects: 16651
Study 34749756 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 critical illness
Number of subjects: 212
Study 34749762 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention to target normoxia
Number of subjects: 0
Study 34749762 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 34749777 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized pharmaceutical plan (PPP) implemented in the intervention phase, including drug reconciliation, daily follow-up, and post-transplantation meetings.
Number of subjects: 1716
Study 34749777 — intervention group
Group type: COMPARATOR
Intervention: Control phase with no personalized pharmaceutical plan.
Number of subjects: 1716
Study 34749788 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based diabetes-modified behavioral activation treatment (HOME DM-BAT) using in-home, nurse telephone-delivered diabetes education and behavioral activation.
Number of subjects: 200
Study 34749788 — intervention group
Group type: COMPARATOR
Intervention: Usual care group using in-home, nurse telephone-delivered health education/supportive therapy.
Number of subjects: 200
Study 34749792 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 105
Study 34749792 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe COVID-19 patients
Number of subjects: 105
Study 34749816 — intervention group
Group type: EXPERIMENTAL
Intervention: QBSAfe agenda setting kit (ASK)
Number of subjects: 0
Study 34749823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense leg resistance and dynamic exercise programme (up to six physiotherapy sessions over 3 months, home exercises at least three times per week)
Number of subjects: 15
Study 34749823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense leg resistance and dynamic exercise programme
Number of subjects: 15
Study 34749885 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitor therapy
Number of subjects: 0
Study 34750014 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine based on prefusion-stabilized spike trimer with alum/CpG adjuvants
Number of subjects: 0
Study 34750057 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (ESK) plus oral antidepressant during induction phase (4 weeks)
Number of subjects: 802
Study 34750057 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (ESK) plus oral antidepressant during optimization/maintenance phase (week 12)
Number of subjects: 802
Study 34750057 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs) during induction phase
Number of subjects: 802
Study 34750057 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious TEAEs during induction phase
Number of subjects: 802
Study 34750057 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAEs of increased blood pressure during induction phase
Number of subjects: 802
Study 34750057 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls during induction phase
Number of subjects: 802
Study 34750057 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs) during optimization/maintenance phase
Number of subjects: 802
Study 34750057 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious TEAEs during optimization/maintenance phase
Number of subjects: 802
Study 34750057 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAEs of increased blood pressure during optimization/maintenance phase
Number of subjects: 802
Study 34750057 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls during optimization/maintenance phase
Number of subjects: 802
Study 34750057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tests
Number of subjects: 802
Study 34750081 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg subcutaneously monthly (every 2 weeks if on apheresis)
Number of subjects: 30
Study 34750081 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 30
Study 34750161 — intervention group
Group type: EXPERIMENTAL
Intervention: Airflow limitation in kidney transplant recipients
Number of subjects: 539
Study 34750161 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 539
Study 34750160 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term hemodialysis patients
Number of subjects: 22
Study 34750160 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 22
Study 34750296 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin (RMD) as latency-reversing agent
Number of subjects: 15
Study 34750296 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched clinical characteristics, n=10)
Number of subjects: 15
Study 34750494 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Arm Sequential Trial with Efficient Recruitment (MASTER) design
Number of subjects: 0
Study 34750494 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel multi-arm multi-stage trial
Number of subjects: 0
Study 34750494 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-arm trials in sequence with interim analyses
Number of subjects: 0
Study 34750557 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus platinum-pemetrexed chemotherapy
Number of subjects: 55
Study 34750557 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and pemetrexed chemotherapy (historical control)
Number of subjects: 55
Study 34750637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab 1, 3, or 10 mg/kg intravenously every 2 weeks (part 1)
Number of subjects: 34
Study 34750637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab 500 mg every 3 weeks (Q3W)
Number of subjects: 34
Study 34750637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab 1000 mg every 6 weeks (Q6W)
Number of subjects: 34
Study 34750637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab (all doses)
Number of subjects: 34
Study 34750642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry products consumption
Number of subjects: 0
Study 34750642 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical techniques (PCA, cluster analysis, PLS-DA)
Number of subjects: 0
Study 34750648 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year ICU survivors performing a maximal CPET (N=313)
Number of subjects: 361
Study 34750648 — intervention group
Group type: COMPARATOR
Intervention: Controls (N=49)
Number of subjects: 361
Study 34750659 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels indicating pre-/diabetic state in patients undergoing major surgery
Number of subjects: 139
Study 34750659 — intervention group
Group type: EXPERIMENTAL
Intervention: Major surgery
Number of subjects: 139
Study 34750659 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed pre-/diabetic state
Number of subjects: 139
Study 34750990 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan
Number of subjects: 440
Study 34751002 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy (AST) discussion referrals
Number of subjects: 618
Study 34751002 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant sunitinib
Number of subjects: 618
Study 34751002 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant immunotherapy trials
Number of subjects: 618
Study 34751002 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision not to receive AST
Number of subjects: 618
Study 34751002 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral frequency by individual surgeons
Number of subjects: 618
Study 34751002 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall referral trends
Number of subjects: 618
Study 34751159 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography and biomarkers assessment in patients with COVID-19
Number of subjects: 150
Study 34751259 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS vaccine (single intramuscular injection)
Number of subjects: 24
Study 34751457 — intervention group
Group type: EXPERIMENTAL
Intervention: African-centered coping strategies
Number of subjects: 95
Study 34751457 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 95
Study 34751514 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental obesity
Number of subjects: 280
Study 34751514 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental elevated blood pressure/hypertension
Number of subjects: 280
Study 34751617 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) treatment
Number of subjects: 21
Study 34751663 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-worn inertial measurement units (IMUs) for gait assessment
Number of subjects: 30
Study 34751663 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-worn inertial measurement units (IMUs) for gait assessment with pain intensity as a covariate
Number of subjects: 30
Study 34751663 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 34751666 — intervention group
Group type: EXPERIMENTAL
Intervention: Purrble (interactive plush toy)
Number of subjects: 134
Study 34751666 — intervention group
Group type: COMPARATOR
Intervention: Active control (noninteractive plush toy)
Number of subjects: 134
Study 34752208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 34752484 — intervention group
Group type: EXPERIMENTAL
Intervention: Maier-Philip-6 HAMD subset scale
Number of subjects: 136
Study 34752484 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset scales and full versions of HAMD
Number of subjects: 136
Study 34752484 — intervention group
Group type: EXPERIMENTAL
Intervention: Early improvement on subset scales and full versions
Number of subjects: 136
Study 34752484 — intervention group
Group type: EXPERIMENTAL
Intervention: Four HAMD-24 items
Number of subjects: 136
Study 34752484 — intervention group
Group type: EXPERIMENTAL
Intervention: One HAMD-24 item
Number of subjects: 136
Study 34752491 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) and Deep Learning (DL) approaches applied to fetuses and newborns with CDH for predicting neonatal pulmonary hypertension (PH)
Number of subjects: 0
Study 34752491 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) and Deep Learning (DL) approaches
Number of subjects: 0
Study 34752714 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated opioid use
Number of subjects: 479
Study 34752714 — intervention group
Group type: COMPARATOR
Intervention: Stable buprenorphine treatment
Number of subjects: 479
Study 34752951 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 201
Study 34752951 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological procedure
Number of subjects: 201
Study 34752951 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 201
Study 34752951 — intervention group
Group type: EXPERIMENTAL
Intervention: Defunctioning stoma
Number of subjects: 201
Study 34752951 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 201
Study 34753208 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing surgical face masks during exercise
Number of subjects: 32
Study 34753208 — intervention group
Group type: COMPARATOR
Intervention: No surgical face masks during exercise
Number of subjects: 32
Study 34753292 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2411
Study 34753292 — intervention group
Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 2411
Study 34753444 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D methods of LA volume detection
Number of subjects: 60
Study 34753444 — intervention group
Group type: COMPARATOR
Intervention: 2D methods of LA volume detection
Number of subjects: 60
Study 34753703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab added to first-line chemotherapy (CT) in SCC patients with positive EGFR FISH and IHC (N=58)
Number of subjects: 1313
Study 34753703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab added to CT in SCC patients
Number of subjects: 1313
Study 34753703 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT without cetuximab) in SCC patients
Number of subjects: 1313
Study 34753703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab added to CT in Non-SCC patients
Number of subjects: 1313
Study 34753762 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of an unspecified intervention (not detailed in the abstract)
Number of subjects: 0
Study 34753762 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 34753777 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab 1 mg/kg plus Nivolumab 240 mg
Number of subjects: 114
Study 34753871 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital pill system (DPS)
Number of subjects: 16
Study 34753870 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) interruption after achieving >99.5% host cell replacement in peripheral blood by day 147.
Number of subjects: 1
Study 34753870 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-alloBMT HIV DNA and cell-associated RNA isolation from peripheral blood mononuclear cells and resting memory CD4+ T cells.
Number of subjects: 1
Study 34753870 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral rebound sequences from plasma and CSF.
Number of subjects: 1
Study 34753894 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 COVID-19 vaccine (Moderna) - 2 doses
Number of subjects: 800
Study 34754076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral delivery of plasmids encoding IL-12 and anti-PD-1 antibody
Number of subjects: 0
Study 34754076 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination of IL-12, anti-PD-1, and anti-CTLA-4 antibodies
Number of subjects: 0
Study 34754076 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-based immunotherapies
Number of subjects: 0
Study 34754193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer Hydrochloride (SH) 2,400 mg
Number of subjects: 34
Study 34754193 — intervention group
Group type: COMPARATOR
Intervention: Lanthanum Carbonate (LC) 1,000 mg
Number of subjects: 34
Study 34754193 — intervention group
Group type: COMPARATOR
Intervention: Both SH and LC
Number of subjects: 34
Study 34754421 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34754421 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring for postoperative complications
Number of subjects: 0
Study 34754429 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD-specific pain assessment tool (APAT) administered longitudinally in a randomized high-water intake trial.
Number of subjects: 39
Study 34754429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain severity and associated analgesic use in ADPKD participants.
Number of subjects: 39
Study 34755128 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter swimming
Number of subjects: 0
Study 34755128 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34755131 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab treatment
Number of subjects: 12
Study 34755137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) administered biweekly for 3 to 4 doses before surgery
Number of subjects: 12
Study 34755248 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/MRI features in patients with metastases
Number of subjects: 101
Study 34755248 — intervention group
Group type: COMPARATOR
Intervention: PET/MRI features in patients without metastases
Number of subjects: 101
Study 34755248 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI features
Number of subjects: 101
Study 34755317 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional bias to threat
Number of subjects: 0
Study 34755598 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity as a risk factor for pulmonary hypertension (PH) in untreated obesity hypoventilation syndrome (OHS)
Number of subjects: 246
Study 34755598 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic interventions targeting weight loss
Number of subjects: 246
Study 34755881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep macrostructure measurements
Number of subjects: 91
Study 34755881 — intervention group
Group type: EXPERIMENTAL
Intervention: Spindle features during first sleep cycle
Number of subjects: 91
Study 34755881 — intervention group
Group type: COMPARATOR
Intervention: Comparison of spindle features by sex
Number of subjects: 91
Study 34755881 — intervention group
Group type: EXPERIMENTAL
Intervention: Second sleep cycle measurements
Number of subjects: 91
Study 34756569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic artificial intelligence approach using Bayesian joint models
Number of subjects: 13608
Study 34756674 — intervention group
Group type: EXPERIMENTAL
Intervention: High density lipoprotein (HDL) particle concentration in AH
Number of subjects: 365
Study 34756674 — intervention group
Group type: COMPARATOR
Intervention: High density lipoprotein (HDL) particle concentration in heavy drinkers
Number of subjects: 365
Study 34756674 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL particle concentration in AH patients
Number of subjects: 365
Study 34756674 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL particle concentration < 3.5 μmol/L and total cholesterol ≤ 96 mg/dL in AH patients
Number of subjects: 365
Study 34756943 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 368
Study 34756943 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS scores
Number of subjects: 368
Study 34756943 — intervention group
Group type: COMPARATOR
Intervention: Initial anxiety or depression status
Number of subjects: 368
Study 34757189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation interrupted
Number of subjects: 1795